Momelotinib Clinical Trials

2 actively recruiting trials across 2 locations

▼ -1 trial since June 2026

Also known as: OJJAARA

Pipeline

Early 1: 1Phase 1: 1

Top Sponsors

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
Janssen Research & Development, LLC1

Indications

Cancer2
Chronic Neutrophilic Leukemia1
Myeloproliferative Overlap Neoplasms1
Myelofibrosis1
Myeloproliferative Disorders1

Duarte, California1 trial

A Study of JNJ-88549968 for the Treatment of Calreticulin (CALR)-Mutated Myeloproliferative Neoplasms

City of Hope

Phase 1

Baltimore, Maryland1 trial

Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Overlap Neoplasms and Chronic Neutrophilic Leukemia

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Early 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.